Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportTheranostics

The effect of Lu-177 Pluvicto therapy treatments on PSA levels

Kaitlyn Neefe, Stacey Schmitz and Carlyn Johnson
Journal of Nuclear Medicine June 2023, 64 (supplement 1) TS15;
Kaitlyn Neefe
1Marshfield Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stacey Schmitz
1Marshfield Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlyn Johnson
1Marshfield Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

TS15

Introduction: As medicine progresses, new options for treating and managing prostate cancer have emerged. Pluvicto (Lu-177 vipivotide tetraxetan) is a radiopharmaceutical used to treat patients with prostate specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC). Pluvicto targets the PSMA biomarkers on the outside of prostate cancer cells and delivers a small amount of radiation to kill the cancer cells. Pluvicto therapy has been shown to decrease prostate specific antigen (PSA) levels by 50% in 46% of patients who receive the treatment who are also utilizing best standards of care. The purpose of this study was to determine the percent change in initial (pre-treatment) PSA values to subsequent PSA values in patients with mCRPC undergoing Pluvicto therapy at Marshfield Medical Center.

Novartis. Efficacy of PLUVICTO. https://www.hcp.novartis.com/products/pluvicto/psma-positive-mcrpc/efficacy/#psa-decline. Accessed February 2023.

Methods: This study retrospectively examined 15 patients, between 58-84 years of age (median age = 71.3 years), receiving one to six Pluvicto therapy treatments over the past 15 months at our facility. Of these, 3 patients expired prior to completing the six treatment therapy course, 3 patients withdrew due to declining health, and only two patients have received all six doses of the treatment. Prior to receiving each treatment, lab values were recorded and evaluated to ensure each patient met the criteria to receive treatment. However, only the PSA levels were analyzed for this study. To determine whether the Pluvicto therapy treatments are contributing to a decrease in PSA, percent change calculations were performed between the initial pre-treatment PSA values and the most recently recorded value. Each patient’s individual PSA percent change per dose was evaluated along with the overall PSA percent change for all patients in the study. A separate overall percent change in PSA was also calculated removing the six patients who had either expired or were no longer seeking treatment.

Results: When comparing the patients’ initial pre-treatment PSA to their most recent value, 9 of the Pluvicto therapy patients saw a decrease in PSA and 4 patients saw an increase, which resulted in an average decrease in PSA of 8%. Excluding the six patients no longer receiving treatments, the average change between initial to most recent PSA revealed a 32% decrease. Individually, 33% of patients indicated a decrease in PSA of 50% or greater. Two patients who received one treatment do not have lab values for comparison.

Conclusions: On average, patients undergoing Pluvicto therapy at MMC had an 8% decrease in PSA values between their initial pre-treatment and post-therapy values. Individually, 5 patients saw a decrease of 50% or greater from their initial PSA value. Due to the small number of participants in this study, we obtained a 50% PSA decrease in 33% of our patients receiving Pluvcito therapy rather than 50% PSA decrease in 46% of patients, as stated in the Pluvicto efficacy information. With three deaths and three withdrawals among the small group of participants, it is likely this treatment option was presented to these patients too late, therefore introducing patients to this therapy earlier may be the key to overall better outcomes.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The effect of Lu-177 Pluvicto therapy treatments on PSA levels
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The effect of Lu-177 Pluvicto therapy treatments on PSA levels
Kaitlyn Neefe, Stacey Schmitz, Carlyn Johnson
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) TS15;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The effect of Lu-177 Pluvicto therapy treatments on PSA levels
Kaitlyn Neefe, Stacey Schmitz, Carlyn Johnson
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) TS15;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire